1016TiP LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment

MLA

D. Madoff, et al. “1016TiP LEAP-012 Trial in Progress: Pembrolizumab plus Lenvatinib and Transarterial Chemoembolization (TACE) in Patients with Intermediate-Stage Hepatocellular Carcinoma (HCC) Not Amenable to Curative Treatment.” Annals of Oncology, vol. 31, Sept. 2020, pp. S702–03. EBSCOhost, https://doi.org/10.1016/j.annonc.2020.08.1132.

APA

D. Madoff, Sadahisa Ogasawara, Leonid Dubrovsky, Zhenggang Ren, Masatoshi Kudo, Richard S. Finn, Kalgi Mody, J.J. Li, Abby B. Siegel, Arndt Vogel, Anthony B. El-Khoueiry, & Josep M. Llovet. (2020). 1016TiP LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment. Annals of Oncology, 31, S702–S703. https://doi.org/10.1016/j.annonc.2020.08.1132

Chicago

D. Madoff, Sadahisa Ogasawara, Leonid Dubrovsky, Zhenggang Ren, Masatoshi Kudo, Richard S. Finn, Kalgi Mody, et al. 2020. “1016TiP LEAP-012 Trial in Progress: Pembrolizumab plus Lenvatinib and Transarterial Chemoembolization (TACE) in Patients with Intermediate-Stage Hepatocellular Carcinoma (HCC) Not Amenable to Curative Treatment.” Annals of Oncology 31 (September): S702–3. doi:10.1016/j.annonc.2020.08.1132.